Wall Street brokerages expect that Spark Therapeutics Inc (NASDAQ:ONCE) will post $32.24 million in sales for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Spark Therapeutics’ earnings. The lowest sales estimate is $11.40 million and the highest is $56.10 million. Spark Therapeutics posted sales of $7.41 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 335.1%. The company is expected to issue its next earnings report on Tuesday, February 19th.
According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $84.72 million for the current fiscal year, with estimates ranging from $62.97 million to $119.89 million. For the next year, analysts anticipate that the company will post sales of $119.39 million, with estimates ranging from $72.47 million to $157.06 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.04) by ($0.22). The business had revenue of $10.70 million during the quarter, compared to analyst estimates of $27.44 million. Spark Therapeutics had a negative net margin of 127.82% and a negative return on equity of 14.18%. The firm’s revenue was up 463.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.90) EPS.
ONCE has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $103.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, October 1st. Raymond James restated a “buy” rating on shares of Spark Therapeutics in a report on Friday, September 21st. William Blair restated a “buy” rating on shares of Spark Therapeutics in a report on Friday, September 21st. Zacks Investment Research upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a report on Wednesday, October 10th. Finally, Guggenheim initiated coverage on shares of Spark Therapeutics in a report on Tuesday, October 9th. They set a “buy” rating and a $70.00 price target for the company. One analyst has rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Spark Therapeutics presently has an average rating of “Hold” and a consensus target price of $65.95.
A number of institutional investors have recently bought and sold shares of the stock. Marshall Wace North America L.P. acquired a new stake in Spark Therapeutics in the 3rd quarter valued at approximately $358,000. Marshall Wace LLP acquired a new stake in Spark Therapeutics in the 3rd quarter valued at approximately $2,253,000. Vanguard Group Inc. increased its holdings in Spark Therapeutics by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,823,168 shares of the biotechnology company’s stock valued at $154,005,000 after purchasing an additional 67,846 shares during the last quarter. Macquarie Group Ltd. increased its holdings in Spark Therapeutics by 21.2% in the 3rd quarter. Macquarie Group Ltd. now owns 508,856 shares of the biotechnology company’s stock valued at $27,758,000 after purchasing an additional 88,931 shares during the last quarter. Finally, Sector Gamma AS increased its holdings in Spark Therapeutics by 7.0% in the 3rd quarter. Sector Gamma AS now owns 33,814 shares of the biotechnology company’s stock valued at $1,845,000 after purchasing an additional 2,214 shares during the last quarter.
Shares of NASDAQ ONCE opened at $38.62 on Friday. The company has a market cap of $1.48 billion, a PE ratio of -5.06 and a beta of 2.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.71 and a quick ratio of 10.36. Spark Therapeutics has a 1 year low of $35.63 and a 1 year high of $96.59.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Recommended Story: Treasury Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.